Odona.aiodona.ai

ABBV

scorecard multi-axes · Scorecard agent
Avg target 266.9 · +4.2%
as of 2026-07-23 · 07:09 PM
Radar
68 / 100
Tactical · 1–3 months
Favorable · short term
59 / 100
Strategic · 3 months +
Mixed · long term
The ABBV scorecard reveals a clear divergence between tactical strength and strategic transition risks. Tactically, the stock exhibits a powerful bullish technical setup with price action trending well above all major moving averages. Strategically, however, the company is navigating a high-stakes pivot from its legacy blockbuster Humira to the Skyrizi/Rinvoq franchise, evidenced by robust revenue growth offset by significant earnings compression. While valuation at a 15.7x forward P/E is reasonable for a leader in immunology, the primary risk remains the speed of the new drug ramp-up relative to biosimilar erosion.
Analysts — consensus & targets
Buy31 analysts
24 buy · 6 hold · 1 sell

Analysts maintain a strong buy consensus, banking on the successful revenue transition from Humira to Skyrizi and Rinvoq to offset patent erosion.

Avg target 266.9 · high 328 · low 200 · +4.2%
Trends by horizon log-price channels ±2σ
1Y +8% · R² 0.12
3M +30% · R² 0.89
1M +4% · R² 0.21
Strengths · watch · risks
Strengths
—
Watch
—
Risks
—
Detail by axis
Fundamentals 54
weight · tac 10 | strat 50
While revenue growth remains robust at 12.4%, the significant earnings contraction of -46.2% reflects the intense margin pressure from Humira's patent erosion. The forward P/E of 15.7x suggests a reasonable valuation despite these headwinds.
Valuation69
Profitability55
Growth45
Balance sheet45
Market Data
Macro & sector 60
weight · tac 5 | strat 20
The immunology sector faces intensifying competition from biosimilars and new entrants, creating structural headwinds for legacy assets. However, AbbVie's established footprint in this therapeutic area provides a defensive buffer against broader economic volatility.
Industry Analysis
Chart / technical 78
weight · tac 30 | strat 0
Market Data
Momentum & consensus 74
weight · tac 25 | strat 15
Analyst sentiment is overwhelmingly positive with a 'Buy' consensus across 31 tracked analysts. The average price target suggests a modest upside of approximately 4.2%, supported by steady upward revisions in recent periods.
Market Data
News & catalysts 65
weight · tac 20 | strat 10
The primary catalyst remains the successful commercial ramp-up of Skyrizi and Rinvoq to replace lost Humira revenue. Recent updates suggest this transition is progressing as planned, mitigating the immediate impact of the patent cliff.
Company Reports
Social / sentiment 50
weight · tac 10 | strat 5
Sentiment is characterized by stable, defensive interest from dividend-focused investors rather than retail hype. The stock lacks significant 'crowding' or speculative froth, maintaining a steady profile typical of large-cap pharmaceutical leaders.
Market Sentiment Analysis
Sources
Factual analysis from public research — not personalised investment advice and not a recommendation. Scores are structured reference points, not forecasts. Odona is a decision-support tool.
Press coverage — deep dive

Summary. AbbVie is currently navigating one of the most significant structural transitions in its history. As the company moves past the Humira patent cliff, its valuation and future growth are increasingly tethered to the successful scaling of its next-generation immunology franchise.

Financial Transition & Growth Dynamics

The company's financial profile presents a stark contrast between top-line expansion and bottom-line pressure. A revenue growth rate of 12.4% demonstrates that AbbVie is successfully capturing market share with newer assets. However, the -46.2% earnings growth figure highlights the significant margin compression caused by the loss of exclusivity for Humira and the subsequent rise in biosimilar competition. This transition period requires careful management of operating expenses to maintain long-term profitability.

Technical Trend & Momentum

From a technical perspective, the stock is exhibiting strong bullish characteristics. The price is currently positioned well above its 20-day, 50-day, and 200-day moving averages, supported by a recent bullish SMA crossover. This upward trend, combined with a relatively low RSI of 43, suggests that while momentum is positive, the stock is not yet in overbought territory, leaving room for further price discovery within its current range.

Competitive Landscape & Macro Risks

The macro environment for AbbVie is defined by the intense competition within the immunology and specialty medicine markets. While the patent cliff for Humira introduces significant risk, the rapid adoption of Skyrizi and Rinvoq acts as a critical counterbalance. The primary strategic challenge lies in ensuring that these newer biologics can achieve sufficient scale to offset the revenue erosion from biosimilars while navigating a complex global regulatory landscape.